전체 프로그램

ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved144 programs
AntibodyLimited DatastaleCorvus Pharmaceuticals, Inc.Phase 1

pembrolizumab (Keytruda, CPI-006 + pembrolizumab)

Non-Small Cell Lung Cancer; Renal Cell Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase1#monoclonal-antibody#RenalCellCancer+1
Trials 1Status Active
AntibodyLimited DatastaleIdris BahceApproved

durvalumab (Imfinzi, Consolidation durvalumab)

Non-small Cell Lung Cancer Stage III · Non-small Cell Lung Cancer Stage III

#Non-smallCellLungCancerStageIII#Antibody#Approved#monoclonal-antibody#Idris
Trials 1Status Recruiting
AntibodyLimited DatastaleUniversity of Texas Southwester…Phase 2

durvalumab (Imfinzi, Consolidative Durvalumab)

Non Small Cell Lung Cancer; Lung Cancer Stage III · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#Antibody#Phase2#monoclonal-antibody#LungCancerStageIII+1
Trials 1Status Active
AntibodyLimited DatastaleDizal PharmaceuticalsPhase 2

DZD9008 plus Bevacizumab (DZD9008 plus Bevacizumab)

Non-small Cell Lung Cancer · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#Antibody#Phase2#monoclonal-antibody#Dizal
Trials 1Status Recruiting
AntibodyLimited DatastaleGilead SciencesPhase 2

DOM (Domvanalimab, Domvanalimab (DOM))

Lung Cancer; Advanced or Metastatic Non-Small-Cell Lung Cancer · Lung Cancer

#LungCancer#Antibody#Phase2#monoclonal-antibody#AdvancedorMetastaticNon-Small-Ce+1
Trials 1Status Recruiting
AntibodyLimited DatastaleCelgenePhase 2

Duravalumab (Duravalumab)

Carcinoma, Non-Small-Cell Lung · Carcinoma, Non-Small-Cell Lung

#CarcinomaNon-Small-CellLung#Antibody#Phase2#monoclonal-antibody#Carcinoma+2
Trials 1Status Active
CGTLimited DatastaleBeijing BiotechPhase 2

DLL3/CD56 CAR-NK cells (EB-DART-NK01, EB-DART-NK01 (DLL3/CD56 CAR-NK cells))

Small Cell Lung Cancer (SCLC); Relapsed/Refractory SCLC · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleSecond Affiliated Hospital, Sch…Phase 1

EphA2-targeted CAR-DCs (EphA2-targeted CAR-DCs)

Non-Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
CGTLimited DatastaleSecond Affiliated Hospital, Sch…Phase 1

EphA2-targeted CAR-T Cells (EphA2-targeted CAR-T Cells)

Non-Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
AntibodyLimited DatastaleHunan Province Tumor HospitalPhase 2

IBI-323 combined with bevacizumab plus Platinum (IBI-323 combined with bevacizumab plus Platinum)

Non Small Cell Lung Cancer · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#Antibody#Phase2#monoclonal-antibody#Hunan
Trials 1Status Active
AntibodyLimited DatastaleShanghai Pulmonary Hospital, Sh…Phase 2

IBI310+Sintilimab (IBI310+Sintilimab)

Non Small Cell Lung Cancer · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#Antibody#Phase2#monoclonal-antibody#Shanghai
Trials 1Status Recruiting
AntibodyLimited DatastaleBristol-Myers SquibbPreclinical

nivolumab (Opdivo, Immuno-oncology-based therapy, excluding nivolumab-based regimens, Immuno-oncology-based therapy (excluding nivolumab-based regimens) with chemotherapy)

Non-small Cell Lung Cancer (NSCLC) · Non-small Cell Lung Cancer (NSCLC)

#Non-smallCellLungCancerNSCLC#Antibody#Preclinical#monoclonal-antibody#Bristol-Myers
Trials 1Status Recruiting
AntibodyLimited DatastaleBristol Myers SquibbPhase 2

nivolumab (Opdivo, Ipilimumab plus nivolumab plus guadecitabine)

Melanoma; Non Small Cell Lung Cancer · Melanoma

#Melanoma#Antibody#Phase2#monoclonal-antibody#NonSmallCellLungCancer+1
Trials 1Status Active
AntibodyLimited DatastaleInSightecPhase 3

Iptilimumab (Iptilimumab)

Brain Tumor; Non Small Cell Lung Cancer · Brain Tumor

#BrainTumor#Antibody#Phase3#monoclonal-antibody#NonSmallCellLungCancer+1
Trials 1Status Recruiting
AntibodyLimited DatastaleShanghai Pulmonary Hospital, Sh…Phase 2

LM-108+Sintilimab (LM-108+Sintilimab)

Non Small Cell Lung Cancer · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#Antibody#Phase2#monoclonal-antibody#Shanghai
Trials 1Status Recruiting
AntibodyLimited DatastaleRochePhase 3

Bevacizumab Biosimilar Drug (MB02, MB02 (Bevacizumab Biosimilar Drug))

Non-small Cell Lung Cancer · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#Antibody#Phase3#monoclonal-antibody#Roche
Trials 1Status Active
CGTLimited DatastaleUniversity of PennsylvaniaPhase 1

MOv19-BBz CAR T cells (MOv19-BBz CAR T cells)

Metastatic Non Small Cell Lung Cancer; Recurrent Lung Non-Small Cell Carcinoma · Metastatic Non Small Cell Lung Cancer

#MetastaticNonSmallCellLungCancer#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
AntibodyLimited DatastaleAssistance Publique Hopitaux De…Phase 2

IPH2201 (Monalizumab, Monalizumab (IPH2201))

Non-small Cell Lung Cancer · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#Antibody#Phase2#monoclonal-antibody#Assistance
Trials 1Status Recruiting
AntibodyLimited DatastaleImmunityBio, Inc.Phase 2

atezolizumab (Tecentriq, N-803 + Atezolizumab)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase2#monoclonal-antibody#SmallCellLungCancer+1
Trials 1Status Recruiting
AntibodyLimited DatastaleImmunityBio, Inc.Phase 2

atezolizumab (Tecentriq, N-803 + Atezolizumab + PD-L1 t-haNK)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · PD-L1

#PD-L1#Antibody#Phase2#monoclonal-antibody#Non-SmallCellLungCancer+2
Trials 1Status Recruiting

5 / 8 pages

← PreviousNext →